O
27.14
-2.05 (-7.02%)
| Penutupan Terdahulu | 29.19 |
| Buka | 29.14 |
| Jumlah Dagangan | 872,235 |
| Purata Dagangan (3B) | 3,827,416 |
| Modal Pasaran | 2,175,540,224 |
| Harga / Buku (P/B) | 7.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -2.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.30% |
| Nisbah Semasa (MRQ) | 15.22 |
| Aliran Tunai Operasi (OCF TTM) | -124.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.86 M |
| Pulangan Atas Aset (ROA TTM) | -27.44% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Olema Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.32% |
| % Dimiliki oleh Institusi | 98.70% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Citigroup, 121.08%) | Beli |
| Median | 45.00 (65.81%) | |
| Rendah | 32.00 (JP Morgan, 17.91%) | Beli |
| Purata | 44.67 (64.59%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 29.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 45.00 (65.81%) | Beli | 27.07 |
| Citigroup | 12 Dec 2025 | 60.00 (121.08%) | Beli | 33.05 |
| Goldman Sachs | 11 Dec 2025 | 38.00 (40.01%) | Beli | 31.58 |
| 21 Nov 2025 | 26.00 (-4.20%) | Beli | 23.17 | |
| HC Wainwright & Co. | 11 Dec 2025 | 45.00 (65.81%) | Beli | 31.58 |
| 18 Nov 2025 | 36.00 (32.65%) | Beli | 20.14 | |
| Oppenheimer | 11 Dec 2025 | 48.00 (76.86%) | Beli | 31.58 |
| 18 Nov 2025 | 45.00 (65.81%) | Beli | 20.14 | |
| JP Morgan | 18 Nov 2025 | 32.00 (17.91%) | Beli | 20.14 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HARMON CYRUS | - | 27.75 | -13,489 | -367,579 |
| KOVACS SHANE WILLIAM CHARLES | - | 28.54 | -103,822 | -3,025,596 |
| MYLES DAVID C. | - | 28.48 | -110,000 | -3,120,900 |
| Jumlah Keseluruhan Kuantiti Bersih | -227,311 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,514,074 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 28.29 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HARMON CYRUS | Pengarah | 20 Jan 2026 | Jual (-) | 10,000 | 26.72 | 267,200 |
| KOVACS SHANE WILLIAM CHARLES | Pegawai | 15 Jan 2026 | Jual (-) | 100,000 | 29.19 | 2,919,000 |
| MYLES DAVID C. | Pegawai | 14 Jan 2026 | Jual (-) | 50,000 | 28.77 | 1,438,500 |
| MYLES DAVID C. | Pegawai | 14 Jan 2026 | Pelaksanaan pilihan | 50,000 | - | - |
| HARMON CYRUS | Pengarah | 14 Jan 2026 | Jual (-) | 3,489 | 28.77 | 100,379 |
| MYLES DAVID C. | Pegawai | 13 Jan 2026 | Jual (-) | 50,000 | 27.89 | 1,394,500 |
| MYLES DAVID C. | Pegawai | 13 Jan 2026 | Pelaksanaan pilihan | 50,000 | - | - |
| KOVACS SHANE WILLIAM CHARLES | Pegawai | 13 Jan 2026 | Jual (-) | 3,822 | 27.89 | 106,596 |
| MYLES DAVID C. | Pegawai | 12 Jan 2026 | Jual (-) | 10,000 | 28.79 | 287,900 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |